Skip to content
Study details
Enrolling now

Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery

Baptist Health South Florida
NCT IDNCT04689048ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

20

Study length

about 4.7 years

Ages

18+

Locations

1 site in FL

What this study is about

Researchers are testing whether a new imaging agent, 18F-fluciclovine, can detect which patients are responding to radiation therapy. The trial will also look at how the treated brain metastases change over time using this imaging agent.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take 18F fluciclovine

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

fluciclovine (18F)

Endpoints

Primary: Change in sensitivity for MRI, Change in the standardized uptake value (SUV) parameters

Secondary: Compare change of SUV metrics of 18F-fluciclovine PET, Compare change of SUV metrics of contrast-enhanced MRI